All-cause mortality | Crude HR (95% CIs) | Adjusted HR (95% CIs)* | ||||
---|---|---|---|---|---|---|
Model 1 | Model 2 | |||||
Patients with intact AAA treated by EVAR or OSR (n = 11,785) | ||||||
30-day mortality | 0.84 | (0.44–1.61) | 0.85 | (0.44–1.62) | 0.82 | (0.43–1.57) |
90-day mortality | 1.10 | (0.76–1.58) | 1.04 | (0.72–1.50) | 1.00 | (0.69–1.45) |
Total mortality | 1.45 | (1.26–1.66) | 1.30 | (1.13–1.49) | 1.31 | (1.14–1.50) |
Patients with intact AAA treated by EVAR (n = 7903) | ||||||
30-day mortality | 0.84 | (0.41–1.76) | 0.88 | (0.42–1.82) | 0.87 | (0.21–3.59) |
90-day mortality | 1.06 | (0.71–1.59) | 1.05 | (0.70–1.58) | 1.03 | (0.69–1.54) |
Total mortality | 1.38 | (1.19–1.61) | 1.30 | (1.11–1.51) | 1.31 | (1.12–1.52) |
Patients with intact AAA treated by OSR (n = 3882) | ||||||
30-day mortality | 0.87 | (0.21–3.59) | 0.89 | (0.21–3.68) | 0.55 | (0.13–2.24) |
90-day mortality | 1.06 | (0.43–2.62) | 1.02 | (0.41–2.51) | 1.05 | (0.55–2.00) |
Total mortality | 1.34 | (0.97–1.85) | 1.17 | (0.85–1.62) | 1.21 | (0.87–1.67) |